Cardiac applications of 123I-mIBG imaging

Seminars in Nuclear Medicine

Volumn 41, Issue 5, 2011, Pages 374-387

  Chirumamilla, Amala ^a   Travin, Mark I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMIODARONE; DOXORUBICIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT;

AUTONOMIC INNERVATION; CANCER CHEMOTHERAPY; CARDIAC AUTONOMIC INNERVATION; CAUSE OF DEATH; COMPUTER ASSISTED DIAGNOSIS; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DIABETES MELLITUS; DISEASE COURSE; HEART ARRHYTHMIA; HEART DEATH; HUMAN; ISCHEMIC HEART DISEASE; PARASYMPATHETIC INNERVATION; PATIENT MONITORING; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION; SYNAPSE; ADRENERGIC SYSTEM; ANIMAL; HEART; HEART DISEASE; INNERVATION; METABOLISM; PATHOPHYSIOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

3-IODOBENZYLGUANIDINE; ANIMALS; BIOLOGICAL TRANSPORT; HEART; HEART DISEASES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; SYMPATHETIC NERVOUS SYSTEM;

EID: 79960923863     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.04.001     Document Type: Review

References (115)

1. Carrió I: Cardiac neurotransmission imaging. J Nucl Med 42:1062-1076, 2001
2. Zipes DP: From cell to bedside, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology (ed 2). Philadelphia, PA, W.B. Saunders Co., 1995, pp 441-442
3. Travin MI: Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin 27:311-327, 2009
4. Flotats A, Carrió I: Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 11:587-602, 2004 (Pubitemid 39341804)
5. Verrier RL, Antzelevich C: Autonomic aspects of arrhythmogenesis: The enduring and the new. Curr Opin Cardiol 19:2-11, 2004 (Pubitemid 39107132)
6. Bengel FM, Schwaiger M: Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 11:603-616, 2004 (Pubitemid 39341805)
7. Sisson JC, Wieland DM: Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies. Am J Physiol Imaging 1:96-103, 1986 (Pubitemid 17188385)
8. Manger WM, Hoffman BB: Heart imaging in the diagnosis of pheochromocytoma and assessment of catecholamine uptake. J Nucl Med 24:1194-1196, 1983 (Pubitemid 14218718)
9. Tobes MC, Jacques S, Wieland DM, et al: Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 26:897-907, 1985 (Pubitemid 16001493)
10. Hattori N, Schwaiger M: Metaiodobenzylguanidine scintigraphy of the heart: What have we learnt clinically? Eur J Nucl Med 27:1-6, 2000 (Pubitemid 30097253)
11. Kline RC, Swanson DP, Wieland DM, et al: Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 22:129-132, 1981 (Pubitemid 11143204)
12. Wieland DM, Brown LE, Rogers WL, et al: Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 22:22-31, 1981 (Pubitemid 11213140)
13. Agostini D, Carrio I, Verberne HJ: How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 36:555-559, 2009
14. Carrió I, Flotats A, Estorch M, et al: Cardiac neurotransmission imaging, in Zaret BL, Beller GM (eds): Single Photon Emission Computed Tomography: Clinical Nuclear Cardiology (ed 3).Philadelphia, PA, Elsevier Health Sciences, 2005, pp 577-591
15. Patel AD, Iskandrian AE: MIBG imaging. J Nucl Cardiol 9:75-94, 2002 (Pubitemid 34196234)
16. Chen J, Garcia EV, Galt JR, et al: Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol 13: 251-260, 2006
17. Kuwahara T, Hamada M, Hiwada K: Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J Nucl Med 39:1486-1491, 1998 (Pubitemid 28459873)
18. Matsuo S, Takahashi M, Nakamura Y, et al: Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzylguanidine imaging in silent myocardial ischemia. J Nucl Med 37:712-717, 1996 (Pubitemid 126447778)
19. Nakajima K, Taki J, Tonami N, et al: Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 15:317-323, 1994 (Pubitemid 24163899)
20. Sakamaki F, Satoh T, Nagaya N, et al: Correlation between severity of pulmonary arterial hypertension and 123I-metaiodobenzylguanidine left ventricular imaging. J Nucl Med 41:1127-1133, 2000 (Pubitemid 30463993)
21. Tsuchimochi S, Tamaki N, Tadamura E, et al: Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med 36:969-974, 1995
22. Ogita H, Shimonagata T, Fukunami M, et al: Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: A prospective study. Heart 86:656-660, 2001 (Pubitemid 33086883)
23. Yamada T, Shimonagata T, Fukunami M, et al: Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study. J Am Coll Cardiol 41:231-238, 2003 (Pubitemid 36092191)
24. Dae MW, O'Connell JW, Botvinick EH, et al: Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 79:634-644, 1989 (Pubitemid 19087715)
25. Hattori N, Tamaki N, Hayashi T, et al: Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med 27:1985-1990, 1996 (Pubitemid 26428367)
26. Ji Sang Yong, Travin MI: Radionuclide imaging of cardiac autonomic innervation. J Nucl Cardiol 17:655-666, 2010
27. Okuda K, Nakajima K, Hosoya T, et al: Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac iodine-123 MIBG imaging. J Nucl Cardiol 118:82-89, 2010
28. Somsen GA, Verberne HJ, Fleury E, et al: Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: Implications for clinical studies. J Nucl Cardiol 11:126-133, 2004 (Pubitemid 38949906)
29. Flotats A, Carrió I, Agostini D, et al: Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802-1812, 2010
30. Boogers MJ, Borleffs CJ, Henneman MM, et al: Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 15:2769-2777, 2010
31. Bax JJ, Kraft O, Buxton AE, et al: 123I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 1:131-140, 2008
32. Minardo JD, Tuliv MM, Mock BH, et al: Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 78:1008-1019, 1988
33. Zipes DP: Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation 82:1095-1105, 1990
34. Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ: Cardiac neuronal imaging. Application in the evaluation of cardiac disease. J Nucl Cardiol 15:442-455, 2008
35. Estorch M, Serra-Grima R, Flotats A, et al: Myocardial sympathetic innervation in the athlete's sinus bradycardia. Is there selective inferior myocardial wall denervation? J Nucl Cardiol 7:354-358, 2000 (Pubitemid 30657738)
36. Bulow HP, Stahl F, Lauer B, et al: Alterations of myocardial presynaptic sympathetic innervation in patients with multi-vessel coronary artery disease but without history of myocardial infarction. Nucl Med Commun 24:233-239, 2003
37. American Heart Association: Heart disease and stroke statistics, 2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85-151, 2006
38. Triposkiadis F, Karayannis G, Giamouzis G, et al: The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54:1747-1762, 2009
39. Bristow MR, Ginsburg R, Minobe W, et al: Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205-211, 1982 (Pubitemid 12079105)
40. Backs J, Haunstetter A, Gerber SH, et al: The neuronal norepinephrine transporter in experimental heart failure: Evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 33:461-472, 2001 (Pubitemid 32539003)
41. Chen GP, Tabibiazar R, Branch KR, et al: Cardiac receptor physiology and imaging: An update. J Nucl Cardiol 12:714-730, 2005 (Pubitemid 43033611)
42. Merlet P, Benvenuti C, Moyse D, et al: Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 40:917-923, 1999 (Pubitemid 29269210)
43. Nakata T, Miyamoto K, Doi A, et al: Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 5:579-590, 1998 (Pubitemid 29015414)
44. Agostini D, Verberne HJ, Burchert W, et al: I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: Insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 35:535-546, 2008
45. Jacobson AF, Lombard J, Banerjee G, et al: 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 16:113-121, 2009
46. Jacobson AF, Senior R, Cerqueira MD, et al, ADMIRE-HF Investigators: Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 55:2212-2221, 2010
47. Travin M, Ananthasubramaniam K, Henzlova MJ, et al: Imaging of myocardial symposiumathetic innervation for prediction of cardiac and all-cause mortality in heart failure patients: Analyses from the Admire-HF trial [abstract]. Circulation 120:S350, 2009
48. Wakabayashi T, Nakata T, Hashimoto A, et al: Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 42:1757-1767, 2001 (Pubitemid 34016342)
49. Carrio I, Cowie MR, Yamazaki J, et al: Cardiac sympathetic imaging with mIBG in heart failure. J Am Coll Cardiol Imaging 3:92-100, 2010
50. Agostini D, Belin A, Amar MH, et al: Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: A 123I-MIBG scintigraphic study. J Nucl Med 41:845-851, 2000 (Pubitemid 30266029)
51. Merlet P, Pouillart F: Dubois-Rande J, et al: Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J Nucl Med 40:224-231, 1999 (Pubitemid 29077082)
52. Lotze U, Kaepplinger S, Kober A, et al: Recovery of the cardiac adrenergic nervous system after long-term beta-blocker therapy in idiopathic dilated cardiomyopathy: Assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J Nucl Med 42:49-54, 2001 (Pubitemid 32104777)
53. Gerson MC, Craft LL, McGuire N, et al: Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 9:608-615, 2002 (Pubitemid 36050207)
54. Fujimoto S, Inoue A, Hisatake S, et al: Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 31:1356-1361, 2004 (Pubitemid 39361930)
55. Suwa M, Otake Y, Moriguchi A, et al: Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to betablocker therapy in patients with dilated cardiomyopathy (Erratum in Am Heart J 1997 134 1141). Am Heart J 133:353-358, 1997
56. Toyama T, Aihara Y, Iwasaki T, et al: Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 40:217-223, 1999 (Pubitemid 29077081)
57. Kasama S, Toyama T, Hatori T, et al: Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 28:989-995, 2007 (Pubitemid 47343912)
58. Fukuoka S, Hayashida K, Hirose Y, et al: Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 24:523-529, 1997 (Pubitemid 27239211)
59. Kasama S, Toyama T, Kumakura H, et al: Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 45:661-667, 2005 (Pubitemid 40278963)
60. Somsen GA, Vlies BV, de Milliano PA, et al: Increased myocardial [123-I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 76:218-222, 1996 (Pubitemid 26290519)
61. Takeishi Y, Atsumi H, Fujiwara S, et al: ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38:1085-1089, 1997 (Pubitemid 27339615)
62. Kasama S, Toyama T, Kumakura H, et al: Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 44:884-890, 2003 (Pubitemid 39663398)
63. Kasama S, Toyama T, Kumakura H, et al: Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 43:1279-1285, 2002
64. Kasama S, Toyama T, Kumakura H, et al: Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 41:574-581, 2003 (Pubitemid 36223322)
65. Massie BM, Fisher SG, Deedwania PC, et al and CHF-STAT Investigators: Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 893:2128-2134, 1996
66. Doval HC, Nul DR, Grancelli HO, et al, la en Grupo de Estudio de la Sobrevida I, en Argentina (GESICA): Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344:493-498, 1994 (Pubitemid 24261565)
67. Singh SN, Fetcher RD, Fisher SG, et al, Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333:77-82, 1995
68. Nademanee K, Piwonka RW, Singh BN, et al: Amiodarone and thyroid function. Prog Cardiovasc Dis 31:427-437, 1989 (Pubitemid 19128264)
69. Toyama T, Hoshizaki H, Seki R, et al: Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: Comparison with beta-blocker therapy. J Nucl Cardiol 11:134-141, 2004 (Pubitemid 38949907)
70. Drakos SG, Athanasoulis T, Malliaras KG, et al: Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. J Am Coll Cardiol Imaging 3:64-70, 2010
71. Erol-Yilmaz A, Verberne HJ, Schrama TA, et al: Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 28:304-310, 2005 (Pubitemid 40613059)
72. Gould PA, Kong G, Kalff V, et al: Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace 9:751-756, 2007 (Pubitemid 47371648)
73. Burri H, Sunthorn H, Somsen A, et al: Improvement in cardiac sympathetic nerve activity in responders to resynchronization therapy. Europace 10:374-378, 2008 (Pubitemid 351773736)
74. Udelson JE, Shafer CD, Carrió I: Radionuclide imaging in heart failure: Assessing etiology and outcomes and implications for management. J Nucl Cardiol 9:40S-52S, 2002
75. Matsui T, Tsutamoto T, Maeda K, et al: Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 66:537-543, 2002 (Pubitemid 34733491)
76. Bello D, Fieno DS, Kim RJ, et al: Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 45:1104-1108, 2005 (Pubitemid 40432446)
77. Stanton MS, Zipes DP: Modulation of drug effects by regional sympathetic denervation and supersensitivity. Circulation 84:1709-1714, 1991
78. Yukinaka M, Nomura M, Ito S, et al: Mismatch between myocardial accumulation of 123I-MIBG and 99mTc-MIBI and late ventricular potentials in patients after myocardial infarction: Association with the development of ventricular arrhythmias. Am Heart J 136:859-867, 1998 (Pubitemid 28506887)
79. Jessup M, Abraham WT, Casey DE, et al: Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 53:1343-1382
80. Bardy GH, Lee KL, Mark DB, et al: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237, 2005 (Pubitemid 40110811)
81. Moss AJ, Zareba W, Hall WJ, et al: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883, 2002 (Pubitemid 34984635)
82. Lee DS, Krahn AD, Healey JS, et al: Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database: Investigators of the Ontario ICD database. J Am Coll Cardiol 23:774-782, 2010
83. Buxton AE, Lee KL, Hafley GE, et al: Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study. J Am Coll Cardiol 50:1150-1157, 2007 (Pubitemid 47375017)
84. Arora R, Ferrick KJ, Nakata T, et al: I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 10:121-131, 2003 (Pubitemid 36503797)
85. Nagahara D, Nakata T, Hashimoto A, et al: Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 49:225-233, 2008 (Pubitemid 351225660)
86. Kioka H, Yamada T, Mine T, et al: Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart 93:1213-1218, 2007 (Pubitemid 47492905)
87. Senior R, Agostini D, Travin M, et al: Imaging of myocardial Sympathetic Innervation for Prediction of Arrhythmic Events in Heart Failure Patients: Insights from the ADMIRE-HF Trial [abstract]. Circulation 120:S349, 2009
88. Tamaki S, Yamada T, Okuyama Y, et al: Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 53:426-435, 2009
89. Katoh S, Shishido T, Kutsuzawa D, et al: Iodine-123- metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med 24:679-686, 2010
90. Mitrani RD, Klein LS, Miles WM, et al: Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 22:1344-1353, 1993 (Pubitemid 23316357)
91. Wichter T, Matheja P, Eckardt L, et al: Cardiac autonomic dysfunction in Brugada syndrome. Circulation 105:702-706, 2002 (Pubitemid 34157373)
92. Matsunari I, Schricke U, Bengel FM, et al: Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 101:2579-2585, 2000 (Pubitemid 30350635)
93. Kammerling JJ, Green FJ, Watanabe AM, et al: Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation 76:383-393, 1987 (Pubitemid 17124749)
94. Inoue H, Zipes DP: Results of sympathetic denervation in the canine heart: Supersensitivity that may be arrhythmogenic. Circulation 75:877-887, 1987 (Pubitemid 17052673)
95. Bengel FM, Barthel P, Matsunari I, et al: Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med 40:904-910, 1999 (Pubitemid 29269208)
96. Simões MV, Barthel P, Matsunari I, et al: Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 25:551-557, 2004
97. Sasano T, Abraham MR, Chang KC, et al: Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 51:2266-2275, 2008 (Pubitemid 351754990)
98. Tomoda H, Yoshioka K, Shiina Y, et al: Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina. Am Heart J 128:452-458, 1994
99. Simula S, Vanninen E, Viitanen L, et al: Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary artery disease. J Nucl Med 43:1-7, 2002 (Pubitemid 34101180)
100. Sakata K, Mochizuki M, Yoshida H, et al: Cardiac sympathetic dysfunction contributes to left ventricular remodeling after acute myocardial infarction. Eur J Nucl Med 27:1641-1649, 2000
101. Ewing DJ, Campbell IW, Clarke BF: The natural history of diabetic autonomic neuropathy. Q J Med 49:95-108, 1980 (Pubitemid 10039105)
102. Dyrberg T, Benn J, Christianses JS, et al: Prevalence of autonomic neuropathy measured by simple bedside tests. Diabetologia 20:190-194, 1981 (Pubitemid 11134125)
103. Langer A, Freeman MR, Josse RG, et al: Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 25:610-618, 1995
104. Nagamachi S, Fujita S, Nishii R, et al: Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 13:34-42, 2006 (Pubitemid 43192727)
105. Schwaiblmair M, von Scheidt W, Uberfuhr P, et al: Functional significance of cardiac reinnervation in heart transplant recipients. J Heart Lung Transplant 18:838-845, 1999 (Pubitemid 29469443)
106. Estorch M, Campreciós M, Flotats A, et al: Sympathetic reinnervation of cardiac allografts evaluated by 123I-MIBG imaging. J Nucl Med 40:911-916, 1999 (Pubitemid 29269209)
107. Wakasugi S, Fischman AJ, Babich JW, et al: Metaiodobenzylguanidine: Evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 34:1282-1286, 1993 (Pubitemid 23230356)
108. Olmos RAV, Huinink WWB, Hoeve RFA, et al: Assessment of anthracycline related myocardial adrenergic derangement by 123IMetaiodobenzylguanidine scintigraphy. Eur J Cancer 31:26-31, 1995
109. Carrió I, Estorch M, Berna L, et al: Assessment of anthracycline-related myocardial adrenergic indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36:2024-2049, 1995
110. Olshansky B, Sabbah HN, Hauptman PJ, et al: Parasympathetic nervous system and heart failure: Pathophysiology and potential implications for therapy. Circulation 118:863-871, 2008
111. Arora R, Ng J, Ulphani J, et al: Unique autonomic profile of the pulmonary veins and posterior left atrium. J Am Coll Cardiol 49:1340-1348, 2007 (Pubitemid 46467223)
112. Lellouche N, Buch E, Celigoj A, et al: Functional characterization of atrial electrograms in sinus rhythm delineates sites of parasympathetic innervation in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 50:1324-1331, 2007 (Pubitemid 47454689)
113. Lautamäki R, Tipre D, Bengel FM: Cardiac sympathetic neuronal imaging using PET. Eur J Nucl Med Mol Imaging 34 Suppl 1:S74-S85, 2007 (Pubitemid 46957471)
114. Bozek J, Silva P, Lamoy M, et al: Heart failure imaging in the rat with LMI 1195: A new PET cardiac neuronal imaging agent: Presented at AHA meeting [abstract]. Circulation 120:S362, 2009
115. Srivastava AV, Planeta-Wilson B, Lin S, et al: Tracer kinetic modeling of [18F]LMI 1195, a new PET imaging agent targeting cardiac norepinephrine transporter [abstract]. J Nucl Cardiol 17:272, 2010